The Company’s first commercial product is Neutrolin®, a novel, non-antibiotic antimicrobial solution with CE Marking in Europe for the prevention of costly and dangerous bloodstream infections associated with the use of central venous catheters. Such infections cost the healthcare system a significant amount of money annually and contribute significantly to increased morbidity and mortality. Neutrolin was shown to reduce the infection rate by 96% compared to historical benchmarks in a post-CE Marking observational study. CorMedix is developing Neutrolin as a drug in the United States and is currently in Phase 3 clinical development in patients undergoing chronic hemodialysis via a central venous catheter. Neutrolin was granted FDA Fast Track status and is designated as a Qualified Infectious Disease Product, contributing to up to 10 years of market exclusivity upon potential U.S. approval. In parallel, CorMedix is working to create additional value for its taurolidine-based technology by establishing partnerships in the antimicrobial/anti-inflammatory medical device space, as well as oncology.